SCHEDULE 13G: BlackRock Discloses 6.1% Stake in ITEOS THERAPEUTICS INC
Beneficial Ownership Report (Schedule 13G)
BlackRock Portfolio Management LLC has filed a Schedule 13G, reporting a 6.1% beneficial ownership stake in ITEOS THERAPEUTICS INC as of March 31, 2025.
Summary
- BlackRock Portfolio Management LLC, a Delaware-organized entity and a subsidiary of BlackRock, Inc., has filed a Schedule 13G with the U.S. Securities and Exchange Commission.
- The filing reports beneficial ownership of common stock in ITEOS THERAPEUTICS INC (CUSIP: 46565G104), a company with principal executive offices in Watertown, MA.
- As of March 31, 2025, BlackRock Portfolio Management LLC, on behalf of its reporting business units, beneficially owns an aggregate of 2,329,827 shares of ITEOS THERAPEUTICS INC common stock.
- This aggregate amount represents 6.1% of the total outstanding class of securities.
- BlackRock Portfolio Management LLC holds sole voting power over 2,013,677 shares and sole dispositive power over 2,329,827 shares, with no shared voting or dispositive power.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is a routine regulatory filing. It does not contain positive or negative performance news, but the presence of a major institutional investor like BlackRock can be seen as a neutral to slightly positive signal by the market.
Positives
- The disclosure of a significant stake by a major institutional investor like BlackRock can be viewed positively by the market, potentially indicating confidence in ITEOS THERAPEUTICS INC.
Future Outlook
Not applicable, as this filing is a beneficial ownership report and does not provide forward-looking statements or guidance from the issuer.
Industry Context
This filing indicates a significant passive investment by BlackRock, one of the world's largest asset managers, in ITEOS THERAPEUTICS INC. Such disclosures are routine for large institutional investors when their holdings cross certain thresholds, reflecting their portfolio management activities rather than specific strategic moves related to the issuer's industry.
Stakeholder Impact
- Shareholders: The disclosure of BlackRock's 6.1% stake may provide a degree of confidence to other investors, potentially influencing stock perception.
- Management: Awareness of a significant institutional shareholder like BlackRock may influence management's focus on shareholder value.
Key Dates
| Date | Description |
|---|---|
| 2025-01-28 | Date of Power of Attorney execution by BlackRock Portfolio Management LLC. |
| 2025-03-31 | Date of event which requires filing of this statement, representing the beneficial ownership reporting date. |
| 2025-04-15 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock Portfolio Management LLC, ITEOS THERAPEUTICS INC, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.